Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2011-03-22

Clinical Trial Update: Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia [Phase 2]

View source ↗

Summary

A Phase 2 trial update on telavancin for uncomplicated Staphylococcus aureus bacteremia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Telavancin (telavancin)

Snippet

Sponsor: Cumberland Pharmaceuticals | Conditions: Gram-Positive Bacterial Infections | Phase 2 | Status: COMPLETED | Results posted: 2011-03-22